Remove Article Remove Cell Based Assays Remove Clinical Development
article thumbnail

Archbishop Ussher's guide to efficient selection of development candidates

Molecular Design

I would argue that the L2021 study has absolutely no relevance whatsoever to the selection of compounds for development since the team will have data available that enables them to rule out the vast majority of the project compounds for nomination.

article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

As a product is refined during development and/or as additional properties about a product are discovered, more sophisticated tools are required to better understand its impact on cellular processes and systems within the body. morphological cell changes or alterations in protein production or expression).